The feasibility of nonmyeloablative stem cell transplantation (NST) was evaluated in 22 adults with high-risk ALL. 16/22 patients had advanced disease and 11/22 had Ph+ ALL. Eleven patients received NST as first stem cell transplantation (SCT). Eleven patients had relapses after allogeneic or autologous SCT and underwent a salvage NST. 
Introduction
Nonmyeloablative stem cell transplantation (NST) is currently being investigated as an alternative to standard conditioning regimens. Patients with CML, AML and NHL, who have contraindications against standard high-dose chemotherapy and total body irradiation (TBI) conditioning protocols can be treated with reduced intensity protocols. [1] [2] [3] [4] [5] Fludarabine has been included in most of the preparative regimens due to its immunosuppressive effects. However, the intensity of the conditioning regimens applied varies between the more intensive busulfan-or melphalan-containing therapies 2, 6 and low-dose regimens with 2 Gy TBI. ditioning regimens can lead to stable engraftment, induce mixed or complete donor chimerism and complete remissions, but only five patients with acute lymphoblastic leukemia (ALL) were treated in these studies. 2, 4, 5 Older patients with ALL, patients with active infections, compromised organ function and those with relapsed ALL after allogeneic stem cell transplantation (SCT) are considered ineligible for standard conditioning because of the anticipated increased transplant-related mortality (TRM).
Allogeneic stem cell transplantation with dose-reduced conditioning could offer a curative option to these patients.
The 22 adult patients reported here represent the largest number of patients with high-risk ALL who received NST because of contraindications against standard conditioning. Our goal was to investigate the feasibility of NST in ALL patients with a special focus on toxicity, induction of a GVL effect and remission rates.
Patients and methods
Twenty-two high-risk ALL patients of the German multicenter acute lymphoblastic leukemia studies (GM-ALL) underwent NST in a pilot study in 13 German transplant centers. Highrisk patients were defined according to the GM-ALL criteria 7 and comprised 16 patients with active disease, two patients in CR1 (Ph+ ALL; high white blood cell count at diagnosis), two patients in CR2, one patient in CR2 after relapse after SCT and one patient with graft failure (Table 1) .
Median age was 38 years (21 to 58 years), 12 were males and 10 females. Patients were transplanted from HLA-identical related donors (n = 13), HLA-mismatch related donor (n = 1) and HLA-identical unrelated donors (n = 8). The protocols for NST had been approved by the local ethic committees. All patients had given written informed consent.
Patients' characteristics First NST:
Eleven patients underwent first NST. Median age was 46 years (21-58). Seven of 11 patients (64%) had active disease before NST. Three of 11 patients had Ph + ALL. Contraindications to standard high-dose conditioning were age above 50 years in four of 11 patients, low Karnofsky index in two of 11 patients, preceding mediastinal irradiation in one of 11 patients and fungal infections in four of 11 patients. 
Salvage NST:
Eleven patients underwent salvage NST after failure of conventional allogeneic (n = 9) and autologous (n = 2) SCT. Median age was 35 years (21-50). The median time between first and second transplant was 8.6 months (1.5 to 98 months). Nine of 11 patients (82%) had persisting leukemia at the time of NST, including both patients after autologous SCT. One of 11 patients was in CR2 and one of 11 had rejected the graft. Eight of 11 patients had a Ph+ ALL. Nine of 11 patients with salvage NST were retransplanted from the same related (n = 8) or unrelated (n = 1) donor. Two patients with relapses after autologous transplantation underwent salvage NST from an unrelated donor (Table 1) . None of these patients had received DLI before salvage NST.
Transplant procedure Conditioning regimen:
Patients were mainly treated with fludarabine, busulfan with or without antithymocyte globulin (ATG). One patient (patient 2) received 2 Gy TBI and one patient (patient 19) received melphalan 200 mg/m 2 and 2-CDA 75 mg/m 2 ( Table 2 ). All patients had unmanipulated transplants. Peripheral blood stem cells served as a stem cell source in 18/22 patients and bone marrow in four of 22 patients.
GVHD prophylaxis:
Twenty-one of 22 patients received cyclosporin A (CsA) as immunosuppressive agent (Table 2) . Combination immunosuppression with mycophenolate mofetil, methotrexate or prednisolone was given to nine of 11 patients after first NST and to two of 11 patients after salvage NST. Acute and chronic GVHD were evaluated using established classifications. 8, 9 For demonstration of engraftment, granulocyte counts had to be above 0.5/nl and platelet counts above 20/nl for 3 days without transfusion. Hematologic, cytogenetic and molecular response was evaluated 1, 3, 6 and 12 months after NST. Intrathecal therapy with methotrexate was given routinely after NST.
DLI were given prophylactically, if no GVHD had developed or therapeutically in relapsing or refractory disease.
Statistics
Survival was calculated by Kaplan-Meier estimations and tested using the log-rank test.
Results
Eighteen of 22 patients (82%) engrafted after NST, three of 22 had refractory ALL and one of 22 had a graft failure. Thirteen of 16 patients (81%) with active disease at the time of NST reached CR. Eleven of 13 patients had acute GVHD. Four of 22 patients (18%) are alive in CR at the time of this analysis. Eight of 22 patients (36%) died from leukemia; nine of 22 patients (41%) died from GVHD and infections, one of 22 died after graft failure.
GVHD developed in 15/22 patients (68%), six of eight after unrelated and nine of 14 after related transplant. Seven of 22 patients received DLI. Prophylactic DLI were given in three of seven patients and all developed severe acute or chronic GVHD; four of seven patients received DLI in relapsed or refractory disease (Table 3) .
First NST
After first NST 10/11 patients (91%) engrafted and one of 11 had refractory disease. Six of seven patients with active disease before NST reached CR. GVHD prophylaxis was stopped after a median of 77 days post-transplant. Acute GVHD developed in eight of 11 patients and five of nine evaluable patients had chronic GVHD. DLI were given to four patients (Table 3) . One of four patients (patient 6) had refractory disease and two DLI had no substantial effect on the course of disease. One of four (patient 2) had relapsed before DLI and reached subsequent CR without GVHD, but died from infection. Prophylactic DLI were given to two of four patients in CR, acute GVHD ϾII developed in both, one of them (patient 4) relapsed with central nervous system leukemia 2 months later, and the other one, who also received two DLI (patient 8) died from cardiac failure 13 months after DLI with only limited chronic GVHD.
A relapse developed in five patients 3 to 10 months after Leukemia NST, three of five reached subsequent CR after either DLI (patient 2), withdrawal of immunosuppression (patient 5) or treatment with imatinib (patient 9). Median survival is 354 days (95% CI, 119-589 days). At the time of this analysis, three of 11 patients (27%) are alive 5, 14 and 30 months after NST (Figure 1) . Two patients had Ph+ ALL and one had T-ALL, all three had been in CR1 or CR2 before NST. Eight of 11 patients have died, three of 11 from leukemia 6 to 13 months after SCT and five of 11 from transplant-related causes 3 to 14 months after NST.
Salvage NST
After salvage NST eight of 11 patients (73%) engrafted, two of 11 had persistent disease and one of 11 had a second graft failure. Seven of nine patients with active disease before NST reached CR and three of them later relapsed. GVHD prophylaxis was given until day 57 in median. Acute GVHD developed in seven of 10 evaluable patients and chronic GVHD in two of six evaluable patients. Three patients received DLI after salvage NST. Two patients received DLI in refractory disease (patient 15 and 18), but died from disease progression; one patient (patient 21) received DLI in CR and later developed extensive chronic GVHD of the lungs and died from bronchiolitis obliterans ( Table 3) .
Five of 11 patients have died from leukemia 2 to 6 months after salvage NST, one of 11 has died after graft failure. Four of 11 died from transplant-related causes 3 to 18 months after NST.
Median survival is 105 days (95% CI, 17-193). Only one Overall survival. The difference between the two groups was not significant because of the small number of patients. With the given survival the power amounts to 25%. To prove difference with a power of 80%, 50 patients would be needed in every group. of 11 patients (9%), who was transplanted with pro-B-ALL in second CR is alive 19 months after salvage NST (Figure 1 ). All surviving patients after first and salvage NST were in first or second CR before NST. In more advanced disease all patients died due to relapse or TRM. Only temporary remissions could be reached in these patients.
Discussion
This study comprises the greatest number of adults with ALL after NST reported. The patient group is unique in two aspects. Firstly, induction therapy before SCT was identical in all patients (GM-ALL protocol). Secondly, all had unfavorable prognostic criteria with 50% suffering from Ph+ ALL and 76% with uncontrolled disease at the time of NST. Almost 50% of the patients had already failed SCT and underwent salvage NST.
In our study engraftment occurred in 83% after NST and 81% of those with uncontrolled disease reached CR. Therefore, even in advanced ALL a dose-reduced conditioning regimen led to stable engraftment and induced complete remission. No difference between stem cells from bone marrow and peripheral blood could be observed, but patient numbers in both groups are small.
The majority of patients received a fludarabine-based protocol mostly combined with busulfan and ATG. 2 The busulfancontaining regimen is more intensive compared to other conditioning protocols with reduced intensity. 5 This might have contributed to the at least temporary control of active disease.
Although the impact of a GVL effect on the course of ALL after SCT is less clear than in CML, a GVL effect in association with acute and chronic GVHD in ALL can be assumed from published data after standard conditioning. 10, 11 Our data favor a GVL effect in ALL also after NST, since all patients with GVHD achieved CR. Among those reaching CR after NST, 84% had developed acute GVHD. A GVL effect can also be assumed by the fact that two relapsing patients reached subsequent CR either after DLI or withdrawal of immunosuppres-sion. No data are available on the impact of GVL and DLI on central nervous system leukemia, but it can be assumed that donor lymphocytes do not cross the blood-brain barrier in sufficient numbers to induce a GVL effect. This can explain the meningeal relapse in two of our patients with GVHD, who had had central nervous system leukemia before NST.
As expected, DLI had only minor effect in those patients who had already relapsed. Only early intervention before clinical relapse can improve the prognosis of these patients, by inducing a GVL effect. 12, 13 However, this was accompanied by severe GVHD in our patients.
The expectations to nonmyeloablative conditioning are that the high morbidity of standard high-dose radio-and chemotherapy could be reduced, thereby extending the indications for SCT to patients otherwise ineligible for transplantation. This could be demonstrated after first NST in our patient group, because two of the surviving patients were older than 50 years and two survivors had fungal infections at transplant. All three surviving patients after first NST were transplanted in CR.
NST was also feasible for retransplantion after failure of standard SCT in 11 patients, but the results are poor. Only one out of 11 patients survived after salvage NST. This patient was transplanted in CR.
The high incidence of severe acute GVHD and chronic GVHD observed in our patient group exposed them to a high risk of TRM.
The intensity of GVHD prophylaxis in NST is still subject of discussion, but all authors have reported a shortened course of GVHD prophylaxis to induce a GVL effect.
1,2,6,14 Among the 11 patients after salvage NST, TRM was 45%.
TRM after standard high-dose retransplantation is 36 to 51% and disease-free survival after 2 to 3 years is between 14 and 27%. [15] [16] [17] The small subgroup of ALL patients in these studies had an especially poor outcome. Median patient age was about 10 years lower than in our patient group. The short median time of 8.6 months between the first and the second transplant in our study is known to be associated with a worse outcome. 17 Death from leukemia accounted for 50% of all deaths in this subgroup reflecting the advanced and uncontrolled stage of disease.
In conclusion, NST can eradicate ALL in high-risk patients transplanted in CR. Even patients with Ph+ ALL, active infections or older patients could benefit from NST. A GVL effect seems to play an important role in remission induction and maintenance. If patients with ALL have uncontrolled disease, NST will probably cure very few patients.
